Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic

A systematic review from 1 January to 30 June 2020 revealed 42 patients with Guillain-Barré syndrome (GBS) associated with SARS-CoV-2 infection. Single cases and small series were reported from 13 countries, the majority from Europe (79.4%) and especially from Italy (30.9%). SARS-CoV-2 infection was...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology, neurosurgery and psychiatry Vol. 91; no. 10; pp. 1105 - 1110
Main Authors: Uncini, Antonino, Vallat, Jean-Michel, Jacobs, Bart C
Format: Journal Article
Language:English
Published: England BMJ Publishing Group Ltd 01.10.2020
BMJ Publishing Group LTD
Subjects:
Adult
Aged
Ataxia
Betacoronavirus
Coronavirus Infections - complications
Coronavirus Infections - diagnosis
Coronavirus Infections - therapy
Coronaviruses
COVID-19
Cytomegalovirus
Disease transmission
Encephalitis
Female
Fever
Guillain-Barre syndrome
Guillain-Barre Syndrome - diagnosis
Guillain-Barre Syndrome - therapy
Guillain-Barre Syndrome - virology
Humans
Infections
Laboratories
Male
Middle Aged
Neuromuscular
neurovirology
Pandemics
Patients
Pneumonia
Pneumonia, Viral - complications
Pneumonia, Viral - diagnosis
Pneumonia, Viral - therapy
SARS-CoV-2
Serology
Severe acute respiratory syndrome coronavirus 2
Systematic review
systematic reviews
Ventilators
Young Adult
Italy
China
Guillain-Barre syndrome
neurovirology
systematic reviews
ISSN:0022-3050, 1468-330X, 1468-330X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract A systematic review from 1 January to 30 June 2020 revealed 42 patients with Guillain-Barré syndrome (GBS) associated with SARS-CoV-2 infection. Single cases and small series were reported from 13 countries, the majority from Europe (79.4%) and especially from Italy (30.9%). SARS-CoV-2 infection was demonstrated by nasopharyngeal swab (85.7%) and serology (14.3%). Median time between COVID-19 and GBS onset in 36 patients was 11.5 days (IQR: 7.7–16). The most common clinical features were: limb weakness (76.2%), hypoareflexia (80.9 %), sensory disturbances (66.7 %) and facial palsy (38.1%). Dysautonomia occurred in 19%, respiratory failure in 33.3% and 40.5% of patients were admitted in intensive care unit. Most patients (71.4%) had the classical clinical presentation but virtually all GBS variants and subtypes were reported. Cerebrospinal fluid (CSF) albumin-cytological dissociation was found in 28/36 (77.8%) and PCR for SARS-CoV-2 was negative in 25/25 patients. Electrodiagnosis was demyelinating in 80.5% and levels 1 and 2 of Brighton criteria of diagnostic certainty, when applicable, were fulfilled in 94.5% patients. Antiganglioside antibodies were positive in only 1/22 patients. Treatments were intravenous immunoglobulin and/or plasma exchange (92.8%) with, at short-time follow-up, definite improvement or recovery in 62.1% of patients. One patient died. In conclusion, the most frequent phenotype of GBS in SARS-CoV-2 infection is the classical sensorimotor demyelinating GBS responding to the usual treatments. The time interval between infectious and neuropathic symptoms, absence of CSF pleocytosis and negative PCR support a postinfectious mechanism. The abundance of reports suggests a pathogenic link between SARS-CoV-2 infection and GBS but a case-control study is greatly needed.
AbstractList A systematic review from 1 January to 30 June 2020 revealed 42 patients with Guillain-Barré syndrome (GBS) associated with SARS-CoV-2 infection. Single cases and small series were reported from 13 countries, the majority from Europe (79.4%) and especially from Italy (30.9%). SARS-CoV-2 infection was demonstrated by nasopharyngeal swab (85.7%) and serology (14.3%). Median time between COVID-19 and GBS onset in 36 patients was 11.5 days (IQR: 7.7–16). The most common clinical features were: limb weakness (76.2%), hypoareflexia (80.9 %), sensory disturbances (66.7 %) and facial palsy (38.1%). Dysautonomia occurred in 19%, respiratory failure in 33.3% and 40.5% of patients were admitted in intensive care unit. Most patients (71.4%) had the classical clinical presentation but virtually all GBS variants and subtypes were reported. Cerebrospinal fluid (CSF) albumin-cytological dissociation was found in 28/36 (77.8%) and PCR for SARS-CoV-2 was negative in 25/25 patients. Electrodiagnosis was demyelinating in 80.5% and levels 1 and 2 of Brighton criteria of diagnostic certainty, when applicable, were fulfilled in 94.5% patients. Antiganglioside antibodies were positive in only 1/22 patients. Treatments were intravenous immunoglobulin and/or plasma exchange (92.8%) with, at short-time follow-up, definite improvement or recovery in 62.1% of patients. One patient died. In conclusion, the most frequent phenotype of GBS in SARS-CoV-2 infection is the classical sensorimotor demyelinating GBS responding to the usual treatments. The time interval between infectious and neuropathic symptoms, absence of CSF pleocytosis and negative PCR support a postinfectious mechanism. The abundance of reports suggests a pathogenic link between SARS-CoV-2 infection and GBS but a case-control study is greatly needed.
A systematic review from 1 January to 30 June 2020 revealed 42 patients with Guillain-Barré syndrome (GBS) associated with SARS-CoV-2 infection. Single cases and small series were reported from 13 countries, the majority from Europe (79.4%) and especially from Italy (30.9%). SARS-CoV-2 infection was demonstrated by nasopharyngeal swab (85.7%) and serology (14.3%). Median time between COVID-19 and GBS onset in 36 patients was 11.5 days (IQR: 7.7-16). The most common clinical features were: limb weakness (76.2%), hypoareflexia (80.9 %), sensory disturbances (66.7 %) and facial palsy (38.1%). Dysautonomia occurred in 19%, respiratory failure in 33.3% and 40.5% of patients were admitted in intensive care unit. Most patients (71.4%) had the classical clinical presentation but virtually all GBS variants and subtypes were reported. Cerebrospinal fluid (CSF) albumin-cytological dissociation was found in 28/36 (77.8%) and PCR for SARS-CoV-2 was negative in 25/25 patients. Electrodiagnosis was demyelinating in 80.5% and levels 1 and 2 of Brighton criteria of diagnostic certainty, when applicable, were fulfilled in 94.5% patients. Antiganglioside antibodies were positive in only 1/22 patients. Treatments were intravenous immunoglobulin and/or plasma exchange (92.8%) with, at short-time follow-up, definite improvement or recovery in 62.1% of patients. One patient died. In conclusion, the most frequent phenotype of GBS in SARS-CoV-2 infection is the classical sensorimotor demyelinating GBS responding to the usual treatments. The time interval between infectious and neuropathic symptoms, absence of CSF pleocytosis and negative PCR support a postinfectious mechanism. The abundance of reports suggests a pathogenic link between SARS-CoV-2 infection and GBS but a case-control study is greatly needed.A systematic review from 1 January to 30 June 2020 revealed 42 patients with Guillain-Barré syndrome (GBS) associated with SARS-CoV-2 infection. Single cases and small series were reported from 13 countries, the majority from Europe (79.4%) and especially from Italy (30.9%). SARS-CoV-2 infection was demonstrated by nasopharyngeal swab (85.7%) and serology (14.3%). Median time between COVID-19 and GBS onset in 36 patients was 11.5 days (IQR: 7.7-16). The most common clinical features were: limb weakness (76.2%), hypoareflexia (80.9 %), sensory disturbances (66.7 %) and facial palsy (38.1%). Dysautonomia occurred in 19%, respiratory failure in 33.3% and 40.5% of patients were admitted in intensive care unit. Most patients (71.4%) had the classical clinical presentation but virtually all GBS variants and subtypes were reported. Cerebrospinal fluid (CSF) albumin-cytological dissociation was found in 28/36 (77.8%) and PCR for SARS-CoV-2 was negative in 25/25 patients. Electrodiagnosis was demyelinating in 80.5% and levels 1 and 2 of Brighton criteria of diagnostic certainty, when applicable, were fulfilled in 94.5% patients. Antiganglioside antibodies were positive in only 1/22 patients. Treatments were intravenous immunoglobulin and/or plasma exchange (92.8%) with, at short-time follow-up, definite improvement or recovery in 62.1% of patients. One patient died. In conclusion, the most frequent phenotype of GBS in SARS-CoV-2 infection is the classical sensorimotor demyelinating GBS responding to the usual treatments. The time interval between infectious and neuropathic symptoms, absence of CSF pleocytosis and negative PCR support a postinfectious mechanism. The abundance of reports suggests a pathogenic link between SARS-CoV-2 infection and GBS but a case-control study is greatly needed.
Author Vallat, Jean-Michel
Jacobs, Bart C
Uncini, Antonino
Author_xml – sequence: 1
  givenname: Antonino
  orcidid: 0000-0002-8131-8912
  surname: Uncini
  fullname: Uncini, Antonino
  email: uncini@unich.it
  organization: Department of Neuroscience, Imaging and Clinical Sciences, University “G. d’Annunzio” Chieti-Pescara, Chieti, Italy
– sequence: 2
  givenname: Jean-Michel
  surname: Vallat
  fullname: Vallat, Jean-Michel
  organization: Department of Neurology, National Reference Center for “Rare Peripheral Neuropathies”, CHU Dupuytren, Limoges, France
– sequence: 3
  givenname: Bart C
  surname: Jacobs
  fullname: Jacobs, Bart C
  organization: Departments of Neurology and Immunology, Erasmus MC, Rotterdam, The Netherlands
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32855289$$D View this record in MEDLINE/PubMed
BookMark eNqNkd9qVDEQxoO02G313isJeCNoav6dbOJdXbQWCoJV8e6Q5CQ0y55km-SofSSfwxczh60tFBRzEybz-yYz8x2CvZiiA-AJwceEMPFqHeMWUUwxYpRzRR6ABeFCIsbw1z2wwJhSxHCHD8BhKWs8H6keggNGZddRqRYgn05hs9Ehojc6518_YbmOQ06jgyHCi5OPF2iVviDaIu9sDSm-hjq2qFQda4NLdaOuwcLsvgX3HSYP66WDPuTS0uEHHFOsl2V-3-o4uDHYR2Df601xj2_uI_D53dtPq_fo_MPp2erkHJkOy4q8JF65zmtH_dKKAdsBG0IGzzvllXZ86bUyTBhniBXadB5zPTCuhLLSYM2OwPNd3W1OV5MrtR9Dsa5NG12aSk85k0Iy2smGPruHrtOUY-uuUZwuuWCYNurpDTWZ0Q39NodR5-v-zzYbgHeAzamU7PwtQnA_G9bPhvWzYf3OsCYR9yQ2VD0vumYdNv8SvtgJzbj-n29e3tG3s_0V_w3Ry7dj
CitedBy_id crossref_primary_10_3892_etm_2021_10471
crossref_primary_10_1111_jns_12612
crossref_primary_10_1111_jns_12459
crossref_primary_10_3390_ctn6010007
crossref_primary_10_1016_j_neulet_2021_136040
crossref_primary_10_1111_ene_15497
crossref_primary_10_3389_fneur_2020_613552
crossref_primary_10_1016_j_neucli_2021_02_001
crossref_primary_10_1007_s00277_024_05970_y
crossref_primary_10_1016_j_ejogrb_2021_06_010
crossref_primary_10_3390_ctn6010001
crossref_primary_10_4103_aian_aian_523_22
crossref_primary_10_3892_etm_2021_10348
crossref_primary_10_3892_etm_2022_11389
crossref_primary_10_3390_biomedicines12061248
crossref_primary_10_3389_fneur_2022_886609
crossref_primary_10_1038_s41582_021_00467_y
crossref_primary_10_17650_2222_8721_2021_11_2_17_27
crossref_primary_10_3390_brainsci11121611
crossref_primary_10_1016_j_pediatrneurol_2021_03_011
crossref_primary_10_3201_eid2712_211634
crossref_primary_10_1016_j_jocn_2021_01_002
crossref_primary_10_1136_jnnp_2020_324837
crossref_primary_10_1111_cen3_12644
crossref_primary_10_1093_qjmed_hcab157
crossref_primary_10_1177_15563316211009207
crossref_primary_10_18214_jend_2023_00143
crossref_primary_10_1007_s10072_021_05562_y
crossref_primary_10_1111_ene_16094
crossref_primary_10_1136_bcr_2021_242365
crossref_primary_10_1093_brain_awaa433
crossref_primary_10_1136_bcr_2020_240178
crossref_primary_10_1002_jgf2_481
crossref_primary_10_2147_NSS_S488911
crossref_primary_10_1007_s10072_021_05345_5
crossref_primary_10_1016_j_jocn_2021_01_028
crossref_primary_10_1111_jns_12419
crossref_primary_10_1080_01616412_2022_2056342
crossref_primary_10_31146_1682_8658_ecg_190_6_18_28
crossref_primary_10_1007_s40120_021_00261_4
crossref_primary_10_1515_tnsci_2020_0194
crossref_primary_10_1111_ene_14803
crossref_primary_10_1007_s10354_023_01018_4
crossref_primary_10_1016_j_jns_2021_117517
crossref_primary_10_7759_cureus_17770
crossref_primary_10_1007_s12028_021_01269_2
crossref_primary_10_4103_aian_AIAN_1303_20
crossref_primary_10_1002_ccr3_5638
crossref_primary_10_1128_cmr_00131_24
crossref_primary_10_1016_j_jocn_2022_03_048
crossref_primary_10_1155_2024_8359683
crossref_primary_10_1016_j_jneuroim_2021_577590
crossref_primary_10_3389_fimmu_2023_1258579
crossref_primary_10_33706_jemcr_1099690
crossref_primary_10_1111_ene_14815
crossref_primary_10_3389_fnins_2023_1159929
crossref_primary_10_7759_cureus_23517
crossref_primary_10_4103_aian_AIAN_1272_20
crossref_primary_10_1097_BOR_0000000000000776
crossref_primary_10_1002_jmv_27061
crossref_primary_10_1007_s00415_021_10468_y
crossref_primary_10_1186_s41983_021_00366_5
crossref_primary_10_1155_2023_5380946
crossref_primary_10_1002_hsr2_887
crossref_primary_10_3390_molecules27092903
crossref_primary_10_1097_INF_0000000000003146
crossref_primary_10_1007_s12026_022_09272_1
crossref_primary_10_3390_neurolint14010003
crossref_primary_10_1007_s11910_021_01102_5
crossref_primary_10_1212_WNL_0000000000012344
crossref_primary_10_1016_j_molmed_2021_06_002
crossref_primary_10_4103_1673_5374_327361
crossref_primary_10_3389_fneur_2020_588929
crossref_primary_10_3389_fneur_2023_1191520
crossref_primary_10_1186_s41983_022_00486_6
crossref_primary_10_4103_aian_aian_974_22
crossref_primary_10_1016_j_ejpn_2021_12_014
crossref_primary_10_1186_s40001_023_01055_0
crossref_primary_10_1016_j_bbih_2025_100983
crossref_primary_10_1002_jcb_30683
crossref_primary_10_1002_ccr3_6743
crossref_primary_10_1007_s12035_023_03638_8
crossref_primary_10_1111_ene_14952
crossref_primary_10_3389_fpubh_2022_937008
crossref_primary_10_31083_j_jin2103077
crossref_primary_10_1097_CND_0000000000000369
crossref_primary_10_1002_jca_21883
crossref_primary_10_1017_cjn_2021_128
crossref_primary_10_1016_j_lfs_2020_118568
crossref_primary_10_1093_brain_awab279
crossref_primary_10_3389_fneur_2024_1332364
crossref_primary_10_1093_qjmed_hcac272
crossref_primary_10_1002_ana_26144
crossref_primary_10_1002_ccr3_6451
crossref_primary_10_1097_MOP_0000000000001070
crossref_primary_10_1002_mus_27179
crossref_primary_10_1016_j_jns_2020_117263
Cites_doi 10.1016/j.neurol.2020.04.003
10.1111/ene.14383
10.1111/ene.14398
10.1016/j.clinph.2020.05.003
10.1016/j.idcr.2020.e00771
10.1016/j.healun.2020.03.012
10.1111/jns.12382
10.1001/jamaneurol.2020.1127
10.1016/j.jneuroim.2020.577294
10.1212/NXI.0000000000000785
10.1016/j.nrl.2020.04.007
10.3174/ajnr.A6654
10.1016/S1474-4422(20)30109-5
10.1111/ene.14368
10.1038/nrneurol.2014.138
10.1016/j.bbi.2020.04.074
10.1016/j.jocn.2020.04.062
10.1212/NXI.0000000000000741
10.1016/j.ijantimicag.2020.105960
10.1212/WNL.0000000000009619
10.1093/cid/ciaa248
10.1136/bcr-2020-236182
10.1177/1941874414535215
10.1016/j.jocn.2020.05.016
10.1111/ene.13552
10.1056/NEJMc2009191
10.1101/2020.03.06.20032417
10.1007/s10072-020-04484-5
10.1093/cid/cir074
10.1371/journal.pntd.0008264
10.1097/CND.0000000000000309
10.1002/ana.21484
10.1007/s00415-020-09849-6
10.1007/s10072-020-04449-8
10.1371/journal.pmed.1000097
10.1016/S0140-6736(16)00562-6
10.1016/j.vaccine.2010.06.003
10.1586/1744666X.2013.811119
10.3174/ajnr.A6609
10.1002/jmv.25728
10.3390/v12010014
10.1212/WNL.51.4.1226
10.1016/j.neurol.2020.04.007
10.7861/clinmed.2020-0213
10.1002/mus.26992
10.1007/s00415-020-09907-z
10.1111/ene.14388
10.1007/s00415-020-09912-2
10.1007/s13365-020-00858-9
10.1017/cjn.2020.106
10.1007/s00415-020-09911-3
ContentType Journal Article
Copyright Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage
Copyright_xml – notice: Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
– notice: This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7X7
7XB
88E
88G
88I
8AF
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB0
M0S
M1P
M2M
M2P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
DOI 10.1136/jnnp-2020-324491
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Proquest Health and Medical Complete
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
Science Database (Alumni Edition)
STEM Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
BMJ Journals
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Psychology Database
Science Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

ProQuest One Psychology
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7RV
  name: Nursing & Allied Health Database
  url: https://search.proquest.com/nahs
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-330X
EndPage 1110
ExternalDocumentID 32855289
10_1136_jnnp_2020_324491
jnnp
Genre Systematic Review
Journal Article
GeographicLocations Italy
China
GeographicLocations_xml – name: China
– name: Italy
GroupedDBID ---
.55
.GJ
.VT
0R~
18M
29L
2WC
354
39C
3O-
4.4
40O
41~
53G
5GY
5RE
5VS
7RV
7X7
7~S
88E
88I
8AF
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAUVZ
AAWJN
AAWTL
ABAAH
ABIVO
ABJNI
ABKDF
ABMQD
ABOCM
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOAB
ACOFX
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AI.
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZFZN
AZQEC
BAWUL
BENPR
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DU5
DWQXO
E3Z
EBS
EJD
EX3
F5P
FEDTE
FYUFA
GNUQQ
GX1
H13
HAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
IPO
IPY
ITC
J5H
KQ8
L7B
M1P
M2M
M2P
N9A
NAPCQ
NTWIH
NXWIF
O9-
OK1
OMB
OMG
OVD
P2P
PCD
PHGZT
PQQKQ
PROAC
PSQYO
PSYQQ
Q2X
R53
RHI
RMJ
RPM
RV8
SJN
TEORI
TR2
UKHRP
UPT
UYXKK
V24
VH1
VM9
VVN
W8F
WH7
WOW
X7M
YFH
YQT
YQY
ZGI
AAYXX
ACQHZ
AERUA
AFFHD
CITATION
PHGZM
PJZUB
PPXIY
3V.
CGR
CUY
CVF
ECM
EIF
NPM
PKN
RHF
YCJ
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
ID FETCH-LOGICAL-b508t-f81f9e5fae2f7c6d0cd0b11df459f9ae47fa9b36beb1c6ab5f04ad34969c8b0a3
IEDL.DBID M2P
ISICitedReferencesCount 109
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000573917200019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0022-3050
1468-330X
IngestDate Thu Oct 02 04:16:40 EDT 2025
Tue Oct 07 07:10:21 EDT 2025
Wed Feb 19 02:29:56 EST 2025
Sat Nov 29 02:37:28 EST 2025
Tue Nov 18 22:22:48 EST 2025
Thu Apr 24 22:50:34 EDT 2025
Thu Apr 24 22:50:17 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Guillain-Barre syndrome
neurovirology
systematic reviews
Language English
License This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b508t-f81f9e5fae2f7c6d0cd0b11df459f9ae47fa9b36beb1c6ab5f04ad34969c8b0a3
Notes Review
ObjectType-Article-1
ObjectType-Evidence Based Healthcare-3
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-8131-8912
OpenAccessLink https://jnnp.bmj.com/content/jnnp/91/10/1105.full.pdf
PMID 32855289
PQID 2442746302
PQPubID 2041879
PageCount 6
ParticipantIDs proquest_miscellaneous_2438683258
proquest_journals_2442746302
pubmed_primary_32855289
crossref_primary_10_1136_jnnp_2020_324491
crossref_citationtrail_10_1136_jnnp_2020_324491
bmj_primary_10_1136_jnnp_2020_324491
bmj_journals_10_1136_jnnp_2020_324491
PublicationCentury 2000
PublicationDate 2020-10-01
PublicationDateYYYYMMDD 2020-10-01
PublicationDate_xml – month: 10
  year: 2020
  text: 2020-10-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of neurology, neurosurgery and psychiatry
PublicationTitleAbbrev J Neurol Neurosurg Psychiatry
PublicationTitleAlternate J Neurol Neurosurg Psychiatry
PublicationYear 2020
Publisher BMJ Publishing Group Ltd
BMJ Publishing Group LTD
Publisher_xml – name: BMJ Publishing Group Ltd
– name: BMJ Publishing Group LTD
References Chan, Ebadi, Sarna (R30) 2020
Webb, Wallace, Martin-Lopez (R37) 2020; 13
Juliao Caamaño, Alonso Beato (R22) 2020; 77
Kilinc, van de Pasch, Doets (R36) 2020
Lantos, Strauss, Lin (R29) 2020; 41
Arnaud, Budowski, Ng Wing Tin (R20) 2020; 131
Wasay, Wolfe, Herrold (R50) 1998; 51
Assini, Benedetti, Di Maio (R28) 2020; 41
Ellis, Marquie-Beck, Delaney (R51) 2008; 64
Scheidl, Canseco, Hadji-Naumov (R25) 2020; 25
Oguz-Akarsu, Ozpar, Mirzayev (R32) 2020
Desforges, Le Coupanec, Dubeau (R44) 2019; 12
Fantini, Di Scala, Chahinian (R45) 2020; 55
Qin, Zhou, Hu (R43) 2020; 71
Gigli, Bax, Marini (R23) 2020
Helbok, Beer, Loscher (R35) 2020
Cao-Lormeau, Blake, Mons (R4) 2016; 387
Sedaghat, Karimi (R11) 2020; 76
Siddiqi, Mehra (R48) 2020; 39
Reyes-Bueno, García-Trujillo, Urbaneja (R40) 2020
Leonhard, Bresani-Salvi, Lyra Batista (R49) 2020; 14
El Otmani, El Moutawakil, Rafai (R16) 2020; 176
Zhao, Shen, Zhou (R9) 2020; 19
Wakerley, Yuki (R3) 2013; 9
Coen, Jeanson, Culebras Almeida (R18) 2020; 87
Toscano, Palmerini, Ravaglia (R12) 2020; 382
Ottaviani, Boso, Tranquillini (R21) 2020; 41
Virani, Rabold, Hanson (R14) 2020; 20
Uncini, González-Bravo, Acosta-Ampudia (R5) 2018; 25
Sancho-Saldaña, Lambea-Gil, Liesa (R33) 2020; 20
Qin, You, Lin (R47) 2020
Alberti, Beretta, Piatti (R19) 2020; 7
Lascano, Epiney, Coen (R31) 2020
Camdessanche, Morel, Pozzetto (R10) 2020; 176
Orlikowski, Porcher, Sivadon-Tardy (R2) 2011; 52
Velayos Galán, Del Saz Saucedo, Peinado Postigo (R15) 2020; 35
Padroni, Mastrangelo, Asioli (R17) 2020; 267
Bigaut, Mallaret, Baloglu (R27) 2020; 7
Rana, Lima, Chandra (R38) 2020; 21
Brizzi, Lyons (R46) 2014; 4
Sejvar, Kohl, Gidudu (R6) 2011; 29
Riva, Russo, Falzone (R24) 2020
Farzi, Ayromlou, Jahanbakhsh (R39) 2020; 346
Moher, Liberati, Tetzlaff (R8) 2009; 6
Li, Bai, Hashikawa (R42) 2020; 92
Fernández-Domínguez, Ameijide-Sanluis, García-Cabo (R26) 2020
Mao, Jin, Wang (R1) 2020; 77
Manganotti, Pesavento, Buoite Stella (R34) 2020
Gutiérrez-Ortiz, Méndez-Guerrero, Rodrigo-Rey (R13) 2020; 95
Wakerley, Uncini, Yuki (R7) 2014; 10
Hutchins, Jansen, Comer (R41) 2020
Sancho-Saldaña, Lambea-Gil, Liesa 2020; 20
Manganotti, Pesavento, Buoite Stella 2020
Gigli, Bax, Marini 2020
Riva, Russo, Falzone 2020
Coen, Jeanson, Culebras Almeida 2020; 87
Padroni, Mastrangelo, Asioli 2020; 267
Scheidl, Canseco, Hadji-Naumov 2020; 25
Wakerley, Uncini, Yuki 2014; 10
Sejvar, Kohl, Gidudu 2011; 29
Qin, You, Lin 2020
Velayos Galán, Del Saz Saucedo, Peinado Postigo 2020; 35
Juliao Caamaño, Alonso Beato 2020; 77
Qin, Zhou, Hu 2020; 71
Hutchins, Jansen, Comer 2020
Fernández-Domínguez, Ameijide-Sanluis, García-Cabo 2020
Bigaut, Mallaret, Baloglu 2020; 7
Lascano, Epiney, Coen 2020
Leonhard, Bresani-Salvi, Lyra Batista 2020; 14
Assini, Benedetti, Di Maio 2020; 41
Sedaghat, Karimi 2020; 76
Mao, Jin, Wang 2020; 77
Cao-Lormeau, Blake, Mons 2016; 387
Uncini, González-Bravo, Acosta-Ampudia 2018; 25
Reyes-Bueno, García-Trujillo, Urbaneja 2020
Helbok, Beer, Loscher 2020
Camdessanche, Morel, Pozzetto 2020; 176
Ellis, Marquie-Beck, Delaney 2008; 64
Brizzi, Lyons 2014; 4
Zhao, Shen, Zhou 2020; 19
Lantos, Strauss, Lin 2020; 41
Wakerley, Yuki 2013; 9
Virani, Rabold, Hanson 2020; 20
Siddiqi, Mehra 2020; 39
Oguz-Akarsu, Ozpar, Mirzayev 2020
Fantini, Di Scala, Chahinian 2020; 55
Wasay, Wolfe, Herrold 1998; 51
Gutiérrez-Ortiz, Méndez-Guerrero, Rodrigo-Rey 2020; 95
Alberti, Beretta, Piatti 2020; 7
Ottaviani, Boso, Tranquillini 2020; 41
Orlikowski, Porcher, Sivadon-Tardy 2011; 52
Kilinc, van de Pasch, Doets 2020
Desforges, Le Coupanec, Dubeau 2019; 12
Li, Bai, Hashikawa 2020; 92
Toscano, Palmerini, Ravaglia 2020; 382
El Otmani, El Moutawakil, Rafai 2020; 176
Moher, Liberati, Tetzlaff 2009; 6
Chan, Ebadi, Sarna 2020
Webb, Wallace, Martin-Lopez 2020; 13
Farzi, Ayromlou, Jahanbakhsh 2020; 346
Rana, Lima, Chandra 2020; 21
Arnaud, Budowski, Ng Wing Tin 2020; 131
Velayos Galán (2024111108050902000_91.10.1105.15) 2020; 35
Arnaud (2024111108050902000_91.10.1105.20) 2020; 131
Fantini (2024111108050902000_91.10.1105.45) 2020; 55
Sedaghat (2024111108050902000_91.10.1105.11) 2020; 76
Reyes-Bueno (2024111108050902000_91.10.1105.40) 2020
Ottaviani (2024111108050902000_91.10.1105.21) 2020; 41
2024111108050902000_91.10.1105.46
2024111108050902000_91.10.1105.44
2024111108050902000_91.10.1105.48
Cao-Lormeau (2024111108050902000_91.10.1105.4) 2016; 387
Farzi (2024111108050902000_91.10.1105.39) 2020; 346
2024111108050902000_91.10.1105.7
2024111108050902000_91.10.1105.8
Leonhard (2024111108050902000_91.10.1105.49) 2020; 14
2024111108050902000_91.10.1105.5
2024111108050902000_91.10.1105.19
2024111108050902000_91.10.1105.6
2024111108050902000_91.10.1105.3
2024111108050902000_91.10.1105.2
Wasay (2024111108050902000_91.10.1105.50) 1998; 51
2024111108050902000_91.10.1105.13
Camdessanche (2024111108050902000_91.10.1105.10) 2020; 176
Assini (2024111108050902000_91.10.1105.28) 2020; 41
2024111108050902000_91.10.1105.9
Toscano (2024111108050902000_91.10.1105.12) 2020; 382
Rana (2024111108050902000_91.10.1105.38) 2020; 21
2024111108050902000_91.10.1105.51
Coen (2024111108050902000_91.10.1105.18) 2020; 87
El Otmani (2024111108050902000_91.10.1105.16) 2020; 176
Webb (2024111108050902000_91.10.1105.37) 2020; 13
2024111108050902000_91.10.1105.29
Virani (2024111108050902000_91.10.1105.14) 2020; 20
Lascano (2024111108050902000_91.10.1105.31) 2020
Qin (2024111108050902000_91.10.1105.43) 2020; 71
2024111108050902000_91.10.1105.24
2024111108050902000_91.10.1105.23
2024111108050902000_91.10.1105.27
2024111108050902000_91.10.1105.26
Qin (2024111108050902000_91.10.1105.47) 2020
Hutchins (2024111108050902000_91.10.1105.41) 2020
Juliao Caamaño (2024111108050902000_91.10.1105.22) 2020; 77
Padroni (2024111108050902000_91.10.1105.17) 2020; 267
2024111108050902000_91.10.1105.35
Mao (2024111108050902000_91.10.1105.1) 2020; 77
2024111108050902000_91.10.1105.34
2024111108050902000_91.10.1105.33
2024111108050902000_91.10.1105.32
Kilinc (2024111108050902000_91.10.1105.36) 2020
Li (2024111108050902000_91.10.1105.42) 2020; 92
Scheidl (2024111108050902000_91.10.1105.25) 2020; 25
2024111108050902000_91.10.1105.30
References_xml – volume: 176
  start-page: 516
  year: 2020
  ident: R10
  article-title: COVID-19 may induce Guillain-Barré syndrome
  publication-title: Rev Neurol
  doi: 10.1016/j.neurol.2020.04.003
– year: 2020
  ident: R40
  article-title: Miller-Fisher syndrome after SARS-CoV-2 infection
  publication-title: Eur J Neurol
  doi: 10.1111/ene.14383
– year: 2020
  ident: R36
  article-title: Guillain-Barré syndrome after SARS-CoV-2 infection
  publication-title: Eur J Neurol
  doi: 10.1111/ene.14398
– volume: 131
  start-page: 1652
  year: 2020
  ident: R20
  article-title: Post SARS-CoV-2 Guillain-Barré syndrome
  publication-title: Clin Neurophysiol
  doi: 10.1016/j.clinph.2020.05.003
– volume: 20
  year: 2020
  ident: R14
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2 infection
  publication-title: IDCases
  doi: 10.1016/j.idcr.2020.e00771
– volume: 39
  start-page: 405
  year: 2020
  ident: R48
  article-title: COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal
  publication-title: J Heart Lung Transplant
  doi: 10.1016/j.healun.2020.03.012
– volume: 25
  start-page: 204
  year: 2020
  ident: R25
  article-title: Guillain-Barré syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature
  publication-title: J Peripher Nerv Syst
  doi: 10.1111/jns.12382
– volume: 77
  start-page: 1
  year: 2020
  ident: R1
  article-title: Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2020.1127
– year: 2020
  ident: R35
  article-title: Guillain-Barré syndrome in a patient with antibodies against SARS-CoV-2
  publication-title: Eur J Neurol
– volume: 346
  year: 2020
  ident: R39
  article-title: Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report
  publication-title: J Neuroimmunol
  doi: 10.1016/j.jneuroim.2020.577294
– volume: 7
  year: 2020
  ident: R27
  article-title: Guillain-Barré syndrome related to SARS-CoV-2 infection
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000785
– year: 2020
  ident: R24
  article-title: Post-Infectious Guillain-Barré syndrome related to SARS-CoV-2 infection: a case report
  publication-title: J Neurol
– volume: 35
  start-page: 268
  year: 2020
  ident: R15
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2 infection
  publication-title: Neurologia
  doi: 10.1016/j.nrl.2020.04.007
– year: 2020
  ident: R41
  article-title: Covid-19-associated bifacial weakness with paresthesia subtype of Guillain-Barré syndrome
  publication-title: AJNR Am J Neuroradiol
  doi: 10.3174/ajnr.A6654
– volume: 19
  start-page: 383
  year: 2020
  ident: R9
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(20)30109-5
– year: 2020
  ident: R31
  article-title: SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with favorable outcome
  publication-title: Eur J Neurol
  doi: 10.1111/ene.14368
– volume: 10
  start-page: 537
  year: 2014
  ident: R7
  article-title: Guillain-Barré and Miller Fisher syndromes--new diagnostic classification
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2014.138
– volume: 87
  start-page: 111
  year: 2020
  ident: R18
  article-title: Guillain-Barré syndrome as a complication of SARS-CoV-2 infection
  publication-title: Brain Behav Immun
  doi: 10.1016/j.bbi.2020.04.074
– volume: 76
  start-page: 233
  year: 2020
  ident: R11
  article-title: Guillain Barre syndrome associated with COVID-19 infection: a case report
  publication-title: J Clin Neurosci
  doi: 10.1016/j.jocn.2020.04.062
– volume: 7
  year: 2020
  ident: R19
  article-title: Guillain-Barré syndrome related to COVID-19 infection
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000741
– volume: 55
  year: 2020
  ident: R45
  article-title: Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2020.105960
– volume: 95
  start-page: e601
  year: 2020
  ident: R13
  article-title: Miller Fisher syndrome and polyneuritis cranialis in COVID-19
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000009619
– volume: 71
  start-page: 762
  year: 2020
  ident: R43
  article-title: Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa248
– volume: 13
  year: 2020
  ident: R37
  article-title: Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication
  publication-title: BMJ Case Rep
  doi: 10.1136/bcr-2020-236182
– volume: 4
  start-page: 230
  year: 2014
  ident: R46
  article-title: Peripheral nervous system manifestations of infectious diseases
  publication-title: Neurohospitalist
  doi: 10.1177/1941874414535215
– start-page: 1
  year: 2020
  ident: R26
  article-title: Miller-Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19)
  publication-title: J Neurol
– volume: 77
  start-page: 230
  year: 2020
  ident: R22
  article-title: Facial diplegia, a possible atypical variant of Guillain-Barré syndrome as a rare neurological complication of SARS-CoV-2
  publication-title: J Clin Neurosci
  doi: 10.1016/j.jocn.2020.05.016
– volume: 25
  start-page: 644
  year: 2018
  ident: R5
  article-title: Clinical and nerve conduction features in Guillain-Barré syndrome associated with Zika virus infection in Cúcuta, Colombia
  publication-title: Eur J Neurol
  doi: 10.1111/ene.13552
– volume: 382
  start-page: 2574
  year: 2020
  ident: R12
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2009191
– year: 2020
  ident: R47
  article-title: Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study
  publication-title: medRxiv
  doi: 10.1101/2020.03.06.20032417
– volume: 41
  start-page: 1657
  year: 2020
  ident: R28
  article-title: New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases
  publication-title: Neurol Sci
  doi: 10.1007/s10072-020-04484-5
– volume: 52
  start-page: 837
  year: 2011
  ident: R2
  article-title: Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cir074
– year: 2020
  ident: R32
  article-title: Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection
  publication-title: Muscle Nerve
– volume: 14
  year: 2020
  ident: R49
  article-title: Guillain-Barré syndrome related to Zika virus infection: A systematic review and meta-analysis of the clinical and electrophysiological phenotype
  publication-title: PLoS Negl Trop Dis
  doi: 10.1371/journal.pntd.0008264
– volume: 21
  start-page: 240
  year: 2020
  ident: R38
  article-title: Novel Coronavirus (COVID-19)-Associated Guillain-Barré Syndrome: Case Report
  publication-title: J Clin Neuromuscul Dis
  doi: 10.1097/CND.0000000000000309
– volume: 64
  start-page: 566
  year: 2008
  ident: R51
  article-title: Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy
  publication-title: Ann Neurol
  doi: 10.1002/ana.21484
– volume: 267
  start-page: 1877
  year: 2020
  ident: R17
  article-title: Guillain-Barré syndrome following COVID-19: new infection, old complication?
  publication-title: J Neurol
  doi: 10.1007/s00415-020-09849-6
– volume: 41
  start-page: 1351
  year: 2020
  ident: R21
  article-title: Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital
  publication-title: Neurol Sci
  doi: 10.1007/s10072-020-04449-8
– volume: 6
  year: 2009
  ident: R8
  article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1000097
– volume: 387
  start-page: 1531
  year: 2016
  ident: R4
  article-title: Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(16)00562-6
– volume: 29
  start-page: 599
  year: 2011
  ident: R6
  article-title: Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2010.06.003
– start-page: 1
  year: 2020
  ident: R23
  article-title: Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster?
  publication-title: J Neurol
– volume: 9
  start-page: 627
  year: 2013
  ident: R3
  article-title: Infectious and noninfectious triggers in Guillain-Barré syndrome
  publication-title: Expert Rev Clin Immunol
  doi: 10.1586/1744666X.2013.811119
– volume: 41
  start-page: 1184
  year: 2020
  ident: R29
  article-title: COVID-19-Associated Miller Fisher syndrome: MRI findings
  publication-title: AJNR Am J Neuroradiol
  doi: 10.3174/ajnr.A6609
– volume: 92
  start-page: 552
  year: 2020
  ident: R42
  article-title: The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients
  publication-title: J Med Virol
  doi: 10.1002/jmv.25728
– volume: 12
  year: 2019
  ident: R44
  article-title: Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?
  publication-title: Viruses
  doi: 10.3390/v12010014
– start-page: 1
  year: 2020
  ident: R30
  article-title: Guillain-Barré syndrome with facial diplegia related to SARS-CoV-2 infection
  publication-title: Can J Neurol Sci
– start-page: 1
  year: 2020
  ident: R34
  article-title: Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2
  publication-title: J Neurovirol
– volume: 51
  start-page: 1226
  year: 1998
  ident: R50
  article-title: Chloroquine myopathy and neuropathy with elevated CSF protein
  publication-title: Neurology
  doi: 10.1212/WNL.51.4.1226
– volume: 176
  start-page: 518
  year: 2020
  ident: R16
  article-title: Covid-19 and Guillain-Barré syndrome: more than a coincidence!
  publication-title: Rev Neurol
  doi: 10.1016/j.neurol.2020.04.007
– volume: 20
  start-page: e93
  year: 2020
  ident: R33
  article-title: Guillain–Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection
  publication-title: Clin Med
  doi: 10.7861/clinmed.2020-0213
– volume: 64
  start-page: 566
  year: 2008
  article-title: Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy
  publication-title: Ann Neurol
  doi: 10.1002/ana.21484
– volume: 346
  year: 2020
  article-title: Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report
  publication-title: J Neuroimmunol
  doi: 10.1016/j.jneuroim.2020.577294
– volume: 19
  start-page: 383
  year: 2020
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(20)30109-5
– volume: 13
  year: 2020
  article-title: Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication
  publication-title: BMJ Case Rep
  doi: 10.1136/bcr-2020-236182
– year: 2020
  article-title: Miller-Fisher syndrome after SARS-CoV-2 infection
  publication-title: Eur J Neurol
  doi: 10.1111/ene.14383
– volume: 267
  start-page: 1877
  year: 2020
  article-title: Guillain-Barré syndrome following COVID-19: new infection, old complication?
  publication-title: J Neurol
  doi: 10.1007/s00415-020-09849-6
– volume: 7
  year: 2020
  article-title: Guillain-Barré syndrome related to COVID-19 infection
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000741
– volume: 387
  start-page: 1531
  year: 2016
  article-title: Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(16)00562-6
– volume: 20
  year: 2020
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2 infection
  publication-title: IDCases
  doi: 10.1016/j.idcr.2020.e00771
– volume: 10
  start-page: 537
  year: 2014
  article-title: Guillain-Barré and Miller Fisher syndromes--new diagnostic classification
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2014.138
– volume: 52
  start-page: 837
  year: 2011
  article-title: Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cir074
– year: 2020
  article-title: Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection
  publication-title: Muscle Nerve
– start-page: 1
  year: 2020
  article-title: Miller-Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19)
  publication-title: J Neurol
– volume: 382
  start-page: 2574
  year: 2020
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2009191
– volume: 176
  start-page: 518
  year: 2020
  article-title: Covid-19 and Guillain-Barré syndrome: more than a coincidence!
  publication-title: Rev Neurol
  doi: 10.1016/j.neurol.2020.04.007
– volume: 131
  start-page: 1652
  year: 2020
  article-title: Post SARS-CoV-2 Guillain-Barré syndrome
  publication-title: Clin Neurophysiol
  doi: 10.1016/j.clinph.2020.05.003
– volume: 35
  start-page: 268
  year: 2020
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2 infection
  publication-title: Neurologia
  doi: 10.1016/j.nrl.2020.04.007
– volume: 41
  start-page: 1657
  year: 2020
  article-title: New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases
  publication-title: Neurol Sci
  doi: 10.1007/s10072-020-04484-5
– year: 2020
  article-title: Covid-19-associated bifacial weakness with paresthesia subtype of Guillain-Barré syndrome
  publication-title: AJNR Am J Neuroradiol
  doi: 10.3174/ajnr.A6654
– volume: 14
  year: 2020
  article-title: Guillain-Barré syndrome related to Zika virus infection: A systematic review and meta-analysis of the clinical and electrophysiological phenotype
  publication-title: PLoS Negl Trop Dis
  doi: 10.1371/journal.pntd.0008264
– volume: 95
  start-page: e601
  year: 2020
  article-title: Miller Fisher syndrome and polyneuritis cranialis in COVID-19
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000009619
– start-page: 1
  year: 2020
  article-title: Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster?
  publication-title: J Neurol
– volume: 29
  start-page: 599
  year: 2011
  article-title: Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2010.06.003
– volume: 51
  start-page: 1226
  year: 1998
  article-title: Chloroquine myopathy and neuropathy with elevated CSF protein
  publication-title: Neurology
  doi: 10.1212/WNL.51.4.1226
– volume: 4
  start-page: 230
  year: 2014
  article-title: Peripheral nervous system manifestations of infectious diseases
  publication-title: Neurohospitalist
  doi: 10.1177/1941874414535215
– volume: 87
  start-page: 111
  year: 2020
  article-title: Guillain-Barré syndrome as a complication of SARS-CoV-2 infection
  publication-title: Brain Behav Immun
  doi: 10.1016/j.bbi.2020.04.074
– volume: 92
  start-page: 552
  year: 2020
  article-title: The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients
  publication-title: J Med Virol
  doi: 10.1002/jmv.25728
– year: 2020
  article-title: Guillain-Barré syndrome in a patient with antibodies against SARS-CoV-2
  publication-title: Eur J Neurol
– year: 2020
  article-title: Guillain-Barré syndrome after SARS-CoV-2 infection
  publication-title: Eur J Neurol
  doi: 10.1111/ene.14398
– volume: 55
  year: 2020
  article-title: Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2020.105960
– year: 2020
  article-title: Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study
  publication-title: medRxiv
  doi: 10.1101/2020.03.06.20032417
– year: 2020
  article-title: SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with favorable outcome
  publication-title: Eur J Neurol
  doi: 10.1111/ene.14368
– volume: 176
  start-page: 516
  year: 2020
  article-title: COVID-19 may induce Guillain-Barré syndrome
  publication-title: Rev Neurol
  doi: 10.1016/j.neurol.2020.04.003
– volume: 77
  start-page: 230
  year: 2020
  article-title: Facial diplegia, a possible atypical variant of Guillain-Barré syndrome as a rare neurological complication of SARS-CoV-2
  publication-title: J Clin Neurosci
  doi: 10.1016/j.jocn.2020.05.016
– volume: 20
  start-page: e93
  year: 2020
  article-title: Guillain–Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection
  publication-title: Clin Med
  doi: 10.7861/clinmed.2020-0213
– start-page: 1
  year: 2020
  article-title: Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2
  publication-title: J Neurovirol
– year: 2020
  article-title: Post-Infectious Guillain-Barré syndrome related to SARS-CoV-2 infection: a case report
  publication-title: J Neurol
– volume: 41
  start-page: 1184
  year: 2020
  article-title: COVID-19-Associated Miller Fisher syndrome: MRI findings
  publication-title: AJNR Am J Neuroradiol
  doi: 10.3174/ajnr.A6609
– volume: 21
  start-page: 240
  year: 2020
  article-title: Novel Coronavirus (COVID-19)-Associated Guillain-Barré Syndrome: Case Report
  publication-title: J Clin Neuromuscul Dis
  doi: 10.1097/CND.0000000000000309
– volume: 71
  start-page: 762
  year: 2020
  article-title: Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa248
– volume: 25
  start-page: 644
  year: 2018
  article-title: Clinical and nerve conduction features in Guillain-Barré syndrome associated with Zika virus infection in Cúcuta, Colombia
  publication-title: Eur J Neurol
  doi: 10.1111/ene.13552
– volume: 41
  start-page: 1351
  year: 2020
  article-title: Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital
  publication-title: Neurol Sci
  doi: 10.1007/s10072-020-04449-8
– volume: 7
  year: 2020
  article-title: Guillain-Barré syndrome related to SARS-CoV-2 infection
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000785
– start-page: 1
  year: 2020
  article-title: Guillain-Barré syndrome with facial diplegia related to SARS-CoV-2 infection
  publication-title: Can J Neurol Sci
– volume: 9
  start-page: 627
  year: 2013
  article-title: Infectious and noninfectious triggers in Guillain-Barré syndrome
  publication-title: Expert Rev Clin Immunol
  doi: 10.1586/1744666X.2013.811119
– volume: 77
  start-page: 1
  year: 2020
  article-title: Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2020.1127
– volume: 76
  start-page: 233
  year: 2020
  article-title: Guillain Barre syndrome associated with COVID-19 infection: a case report
  publication-title: J Clin Neurosci
  doi: 10.1016/j.jocn.2020.04.062
– volume: 12
  year: 2019
  article-title: Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?
  publication-title: Viruses
  doi: 10.3390/v12010014
– volume: 39
  start-page: 405
  year: 2020
  article-title: COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal
  publication-title: J Heart Lung Transplant
  doi: 10.1016/j.healun.2020.03.012
– volume: 6
  year: 2009
  article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.1000097
– volume: 25
  start-page: 204
  year: 2020
  article-title: Guillain-Barré syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature
  publication-title: J Peripher Nerv Syst
  doi: 10.1111/jns.12382
– ident: 2024111108050902000_91.10.1105.6
  doi: 10.1016/j.vaccine.2010.06.003
– year: 2020
  ident: 2024111108050902000_91.10.1105.31
  article-title: SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with favorable outcome
  publication-title: Eur J Neurol
  doi: 10.1111/ene.14368
– ident: 2024111108050902000_91.10.1105.9
  doi: 10.1016/S1474-4422(20)30109-5
– volume: 35
  start-page: 268
  year: 2020
  ident: 2024111108050902000_91.10.1105.15
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2 infection
  publication-title: Neurologia
  doi: 10.1016/j.nrl.2020.04.007
– ident: 2024111108050902000_91.10.1105.5
  doi: 10.1111/ene.13552
– volume: 267
  start-page: 1877
  year: 2020
  ident: 2024111108050902000_91.10.1105.17
  article-title: Guillain-Barré syndrome following COVID-19: new infection, old complication?
  publication-title: J Neurol
  doi: 10.1007/s00415-020-09849-6
– volume: 20
  year: 2020
  ident: 2024111108050902000_91.10.1105.14
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2 infection
  publication-title: IDCases
  doi: 10.1016/j.idcr.2020.e00771
– ident: 2024111108050902000_91.10.1105.33
  doi: 10.7861/clinmed.2020-0213
– volume: 51
  start-page: 1226
  year: 1998
  ident: 2024111108050902000_91.10.1105.50
  article-title: Chloroquine myopathy and neuropathy with elevated CSF protein
  publication-title: Neurology
  doi: 10.1212/WNL.51.4.1226
– ident: 2024111108050902000_91.10.1105.2
  doi: 10.1093/cid/cir074
– volume: 41
  start-page: 1351
  year: 2020
  ident: 2024111108050902000_91.10.1105.21
  article-title: Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital
  publication-title: Neurol Sci
  doi: 10.1007/s10072-020-04449-8
– volume: 25
  start-page: 204
  year: 2020
  ident: 2024111108050902000_91.10.1105.25
  article-title: Guillain-Barré syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature
  publication-title: J Peripher Nerv Syst
  doi: 10.1111/jns.12382
– ident: 2024111108050902000_91.10.1105.3
  doi: 10.1586/1744666X.2013.811119
– volume: 176
  start-page: 518
  year: 2020
  ident: 2024111108050902000_91.10.1105.16
  article-title: Covid-19 and Guillain-Barré syndrome: more than a coincidence!
  publication-title: Rev Neurol
  doi: 10.1016/j.neurol.2020.04.007
– year: 2020
  ident: 2024111108050902000_91.10.1105.40
  article-title: Miller-Fisher syndrome after SARS-CoV-2 infection
  publication-title: Eur J Neurol
  doi: 10.1111/ene.14383
– ident: 2024111108050902000_91.10.1105.7
  doi: 10.1038/nrneurol.2014.138
– volume: 387
  start-page: 1531
  year: 2016
  ident: 2024111108050902000_91.10.1105.4
  article-title: Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study
  publication-title: The Lancet
  doi: 10.1016/S0140-6736(16)00562-6
– year: 2020
  ident: 2024111108050902000_91.10.1105.36
  article-title: Guillain-Barré syndrome after SARS-CoV-2 infection
  publication-title: Eur J Neurol
  doi: 10.1111/ene.14398
– volume: 14
  year: 2020
  ident: 2024111108050902000_91.10.1105.49
  article-title: Guillain-Barré syndrome related to Zika virus infection: A systematic review and meta-analysis of the clinical and electrophysiological phenotype
  publication-title: PLoS Negl Trop Dis
  doi: 10.1371/journal.pntd.0008264
– volume: 87
  start-page: 111
  year: 2020
  ident: 2024111108050902000_91.10.1105.18
  article-title: Guillain-Barré syndrome as a complication of SARS-CoV-2 infection
  publication-title: Brain Behav Immun
  doi: 10.1016/j.bbi.2020.04.074
– volume: 176
  start-page: 516
  year: 2020
  ident: 2024111108050902000_91.10.1105.10
  article-title: COVID-19 may induce Guillain-Barré syndrome
  publication-title: Rev Neurol
  doi: 10.1016/j.neurol.2020.04.003
– ident: 2024111108050902000_91.10.1105.32
  doi: 10.1002/mus.26992
– volume: 346
  year: 2020
  ident: 2024111108050902000_91.10.1105.39
  article-title: Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report
  publication-title: J Neuroimmunol
  doi: 10.1016/j.jneuroim.2020.577294
– ident: 2024111108050902000_91.10.1105.24
  doi: 10.1007/s00415-020-09907-z
– volume: 77
  start-page: 1
  year: 2020
  ident: 2024111108050902000_91.10.1105.1
  article-title: Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2020.1127
– ident: 2024111108050902000_91.10.1105.44
  doi: 10.3390/v12010014
– ident: 2024111108050902000_91.10.1105.19
  doi: 10.1212/NXI.0000000000000741
– ident: 2024111108050902000_91.10.1105.8
  doi: 10.1371/journal.pmed.1000097
– ident: 2024111108050902000_91.10.1105.35
  doi: 10.1111/ene.14388
– ident: 2024111108050902000_91.10.1105.27
  doi: 10.1212/NXI.0000000000000785
– ident: 2024111108050902000_91.10.1105.13
  doi: 10.1212/WNL.0000000000009619
– ident: 2024111108050902000_91.10.1105.29
  doi: 10.3174/ajnr.A6609
– ident: 2024111108050902000_91.10.1105.48
  doi: 10.1016/j.healun.2020.03.012
– volume: 77
  start-page: 230
  year: 2020
  ident: 2024111108050902000_91.10.1105.22
  article-title: Facial diplegia, a possible atypical variant of Guillain-Barré syndrome as a rare neurological complication of SARS-CoV-2
  publication-title: J Clin Neurosci
  doi: 10.1016/j.jocn.2020.05.016
– ident: 2024111108050902000_91.10.1105.51
  doi: 10.1002/ana.21484
– volume: 382
  start-page: 2574
  year: 2020
  ident: 2024111108050902000_91.10.1105.12
  article-title: Guillain-Barré syndrome associated with SARS-CoV-2
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2009191
– volume: 55
  year: 2020
  ident: 2024111108050902000_91.10.1105.45
  article-title: Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2020.105960
– volume: 131
  start-page: 1652
  year: 2020
  ident: 2024111108050902000_91.10.1105.20
  article-title: Post SARS-CoV-2 Guillain-Barré syndrome
  publication-title: Clin Neurophysiol
  doi: 10.1016/j.clinph.2020.05.003
– volume: 41
  start-page: 1657
  year: 2020
  ident: 2024111108050902000_91.10.1105.28
  article-title: New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases
  publication-title: Neurol Sci
  doi: 10.1007/s10072-020-04484-5
– year: 2020
  ident: 2024111108050902000_91.10.1105.47
  article-title: Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study
  publication-title: medRxiv
– ident: 2024111108050902000_91.10.1105.26
  doi: 10.1007/s00415-020-09912-2
– year: 2020
  ident: 2024111108050902000_91.10.1105.41
  article-title: Covid-19-associated bifacial weakness with paresthesia subtype of Guillain-Barré syndrome
  publication-title: AJNR Am J Neuroradiol
  doi: 10.3174/ajnr.A6654
– volume: 71
  start-page: 762
  year: 2020
  ident: 2024111108050902000_91.10.1105.43
  article-title: Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa248
– volume: 13
  year: 2020
  ident: 2024111108050902000_91.10.1105.37
  article-title: Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication
  publication-title: BMJ Case Rep
  doi: 10.1136/bcr-2020-236182
– volume: 92
  start-page: 552
  year: 2020
  ident: 2024111108050902000_91.10.1105.42
  article-title: The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients
  publication-title: J Med Virol
  doi: 10.1002/jmv.25728
– volume: 21
  start-page: 240
  year: 2020
  ident: 2024111108050902000_91.10.1105.38
  article-title: Novel Coronavirus (COVID-19)-Associated Guillain-Barré Syndrome: Case Report
  publication-title: J Clin Neuromuscul Dis
  doi: 10.1097/CND.0000000000000309
– ident: 2024111108050902000_91.10.1105.34
  doi: 10.1007/s13365-020-00858-9
– ident: 2024111108050902000_91.10.1105.30
  doi: 10.1017/cjn.2020.106
– ident: 2024111108050902000_91.10.1105.46
  doi: 10.1177/1941874414535215
– volume: 76
  start-page: 233
  year: 2020
  ident: 2024111108050902000_91.10.1105.11
  article-title: Guillain Barre syndrome associated with COVID-19 infection: a case report
  publication-title: J Clin Neurosci
  doi: 10.1016/j.jocn.2020.04.062
– ident: 2024111108050902000_91.10.1105.23
  doi: 10.1007/s00415-020-09911-3
SSID ssj0000089
Score 2.621003
SecondaryResourceType review_article
Snippet A systematic review from 1 January to 30 June 2020 revealed 42 patients with Guillain-Barré syndrome (GBS) associated with SARS-CoV-2 infection. Single cases...
SourceID proquest
pubmed
crossref
bmj
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1105
SubjectTerms Adult
Aged
Ataxia
Betacoronavirus
Coronavirus Infections - complications
Coronavirus Infections - diagnosis
Coronavirus Infections - therapy
Coronaviruses
COVID-19
Cytomegalovirus
Disease transmission
Encephalitis
Female
Fever
Guillain-Barre syndrome
Guillain-Barre Syndrome - diagnosis
Guillain-Barre Syndrome - therapy
Guillain-Barre Syndrome - virology
Humans
Infections
Laboratories
Male
Middle Aged
Neuromuscular
neurovirology
Pandemics
Patients
Pneumonia
Pneumonia, Viral - complications
Pneumonia, Viral - diagnosis
Pneumonia, Viral - therapy
SARS-CoV-2
Serology
Severe acute respiratory syndrome coronavirus 2
Systematic review
systematic reviews
Ventilators
Young Adult
Title Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic
URI https://jnnp.bmj.com/content/91/10/1105.full
https://www.ncbi.nlm.nih.gov/pubmed/32855289
https://www.proquest.com/docview/2442746302
https://www.proquest.com/docview/2438683258
Volume 91
WOSCitedRecordID wos000573917200019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Nursing & Allied Health Database
  customDbUrl:
  eissn: 1468-330X
  dateEnd: 20250609
  omitProxy: false
  ssIdentifier: ssj0000089
  issn: 0022-3050
  databaseCode: 7RV
  dateStart: 19440701
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/nahs
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1468-330X
  dateEnd: 20250609
  omitProxy: false
  ssIdentifier: ssj0000089
  issn: 0022-3050
  databaseCode: BENPR
  dateStart: 19440701
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Proquest Health and Medical Complete
  customDbUrl:
  eissn: 1468-330X
  dateEnd: 20250609
  omitProxy: false
  ssIdentifier: ssj0000089
  issn: 0022-3050
  databaseCode: 7X7
  dateStart: 19440701
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Psychology Database
  customDbUrl:
  eissn: 1468-330X
  dateEnd: 20250609
  omitProxy: false
  ssIdentifier: ssj0000089
  issn: 0022-3050
  databaseCode: M2M
  dateStart: 19440701
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/psychology
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database
  customDbUrl:
  eissn: 1468-330X
  dateEnd: 20250609
  omitProxy: false
  ssIdentifier: ssj0000089
  issn: 0022-3050
  databaseCode: M2P
  dateStart: 19440701
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELbYFiEu_EOXlpWRyoGDtU6cODaXqq1auOxqtYVqb5GT2Goq6myTLOKVeA5eDE9-dumhy4GLpSS2Y2nG9jee8TcIHWoeCCM8TQwPQxJEmSRCGE0Yi6inFFXST5tkE9F0KhYLOesO3KourLJfE5uFOitSOCMfu23IGVCcUf9oeUsgaxR4V7sUGgO065CNByFdE3_2F_wVcs0WTkPauykZH19bu3QaAteHXc_A0DlIbq7vbk73IM5m5zl_-r9jfoaedJgTH7dK8hw90PYFejTpvOovUfl5BbmHcktOVFn-_oV7GgOcW3xxPL8gp8Ul8XEfuGU_YWXdEwDLGm-4oHF7DwYXBjtYiU3ukCWu8p_YjaO-quD9Es6sb_L0Ffp2fvb19AvpcjGQxEG4mjh5GqlDo7RvopRnNM1o4nmZCUJppNJBZJRMGE_c2p9ylYSGBioDNnqZioQq9hrt2MLqPYS1g3x-kHATKRqwJHIWjZZAM-ZlyvjcH6IPThRxN5equDFTGI9BZDGILG5FNkSHUG_ZsnJsqTbuZRqnHe85pN_4vqXFx3WLf_d-0It-M-KN3Ifo_fqzm7fgjFFWFyuowwR3y2kohuhNq17rnzFfhKGzhN9u73wfPW40uAktPEA7dbnS79DD9EedV-UIDaL5JZSLqCnFCO2enE1n8xFMkklTzv4ARZITcw
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFLXagoAN78dAASO1CxbWOHbi2EgIlUJp1XZU0RZ1F5zEFqmoMyQzPD6JDT_Bj-GbxwwsGFZdsExiO3ZyfB_29bkIrRkRSisDQ6yIIhLGuSJSWkM4j2mgNdWKZU2yiXg0kicn6mAJ_ejPwkBYZS8TG0GdlxmskQ-9GvIOlOCUvRh_IpA1CnZX-xQaLSx2zbcv3mWrn--88v93nbGt10eb26TLKkBSb4xMiO-ZVSay2jAbZyKnWU7TIMhtGCmrtAljq1XKReqlWCZ0Glka6hx41VUmU6q5b3cZXQiBWQxCBdnBb-a2VDN2chrRfluUi-Gpc2OPSDiu7EcCjKDL6dnpn8rwLxZuo-m2rv1v3-g6utrZ1HijnQQ30JJxN9Gl_S5q4Baq3kwht1LhyEtdVT-_456mARcOH268PSSb5TvCcB-Y5p5h7fwVGM4TPOe6xu05H1xa7M1mbAtvOeO6-Ir9uCcfarg_hjX5syK7jY7PZcR30IornbmHsPEmLQtTYWNNQ57G3mMzCmjUglxbJtgArftfn3Syok4aN4yLBCCSAESSFiIDtAblxi3ryIJiwx5DSdbxukN6kY8Lajyd1fh366s91OY9nuNsgJ7MHnu5BJtN2plyCmW4FF5dRHKA7rZwnr2MMxlF3tO_v7jxx-jy9tH-XrK3M9p9gK40s6cJo1xFK5Nqah6ii9nnSVFXj5ppiNH788b0L6PNb0M
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61W1Rx4f1YKGCk9sDB2sRJHBsJob4WqsJq1QLqLTiJLVLRZMlmefwk_gLX_rGO89iFA8upB45JbMdOPs98Y49nADY194URrqaGBwH1w1RSIYymnhc6rlKOkiypk02Eo5E4OZHjFfjVnYWxbpWdTKwFdVokdo18gGoIDSjuOWxgWreI8d7w5eQLtRmk7E5rl06jgcih_vENzbfpi4M9_NdbjA333-2-pm2GARojMako9tJIHRilmQkTnjpJ6sSumxo_kEYq7YdGydjjMUq0hKs4MI6vUhtjXSYidpSH7a7CWogkw-_B2s7-aHz0G_kWch6r3AmcbpPU44PTPJ8gPu3hZRyXjQ-6Gp-d_qka_8J3a703vP4_f7EbcK1l22S7mR43YUXnt2D9betPcBvKVzObdSnL6Y4qy_OfpAvgQLKcHG8fHdPd4gNlpHNZy58TleOVpdQVWUTBJs0JIFIYgoSamAw5NZlm3wmOu_o0tfcndrX-LEvuwPtLGfFd6OVFru8D0Uh2mR9zEyrH9-IQbTktbYA1N1WGcdaHLYRB1EqRaVQbaB6PLFwiC5eogUsfNm25SROPZEmxQYenKGkjvtvEI5-X1Hg2r_Hv1jc62C16vMBcH57OH6PEsttQKtfFzJbxBEdFEog-3GugPX-Zx0QQMCEfLG_8CawjlKM3B6PDh3C1nki1f-UG9Kpyph_BleRrlU3Lx-2cJPDxskF9AdomeV0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Guillain-Barr%C3%A9+syndrome+in+SARS-CoV-2+infection%3A+an+instant+systematic+review+of+the+first+six+months+of+pandemic&rft.jtitle=Journal+of+neurology%2C+neurosurgery+and+psychiatry&rft.au=Uncini%2C+Antonino&rft.au=Vallat%2C+Jean-Michel&rft.au=Jacobs%2C+Bart+C&rft.date=2020-10-01&rft.eissn=1468-330X&rft.volume=91&rft.issue=10&rft.spage=1105&rft_id=info:doi/10.1136%2Fjnnp-2020-324491&rft_id=info%3Apmid%2F32855289&rft.externalDocID=32855289
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3050&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3050&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3050&client=summon